pertuzumab + trastuzumab + chemotherapy

Pertuzumab + trastuzumab + chemotherapy is a combination regimen used for the treatment of HER2-positive breast cancer, in both early, locally advanced, and metastatic settings. **Pertuzumab** and **trastuzumab** are humanized monoclonal antibodies targeting different domains of the HER2 (human epidermal growth factor receptor 2) protein, blocking HER2-mediated signaling and promoting cancer cell death. Chemotherapy agents most commonly included are taxanes (e.g., paclitaxel or docetaxel), which disrupt cell division. Dual HER2-blockade with pertuzumab and trastuzumab inhibits HER2 dimerization and activation, resulting in greater antitumor activity than either antibody alone. This regimen is standard-of-care in early, locally advanced, and metastatic HER2-positive breast cancer, and is typically administered with taxane- or anthracycline-based chemotherapy depending on disease stage and risk profile[2][3][4][5][6][7][8].

Other names

THP chemo